Targeted News Service

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of Nubeqa Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer
May 16, 2026

WHIPPANY, New Jersey, May 16 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:

* * *

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA(R) (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

* Primary results from the Phase II ARASEC trial show that NUBEQA(R) (darolutamide) plus androgen deprivation therapy . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form